Previous close | 0.7900 |
Open | 0.8100 |
Bid | 0.7665 x 100 |
Ask | 0.8481 x 100 |
Day's range | 0.7900 - 0.8500 |
52-week range | 0.7820 - 4.2900 |
Volume | |
Avg. volume | 104,282 |
Market cap | 43.489M |
Beta (5Y monthly) | 0.59 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.6400 |
Earnings date | 30 Apr 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.70 |
PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be featured as a late-breaking clinical trial presentation a
The analysts covering Cytosorbents Corporation ( NASDAQ:CTSO ) delivered a dose of negativity to shareholders today, by...
Cytosorbents ( NASDAQ:CTSO ) Full Year 2023 Results Key Financial Results Revenue: US$36.3m (up 4.8% from FY 2022). Net...